Binding of ATP to vascular endothelial growth factor isoform VEGF-A 165is essential for inducing proliferation of human umbilical vein endothelial cells

BMC Biochemistry

Volumn 12, Issue 1, 2011, Pages

  Gast, Ronald E ^a   König, Simone ^a   Rose, Karsten ^a   Ferenz, Katja B ^a   Krieglstein, Josef ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; PURINERGIC P2 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN A 165; GROWTH PROMOTOR; PEPTIDE FRAGMENT; PLASMIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A (138 165); VASCULAR ENDOTHELIAL GROWTH FACTOR A (138-165);

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; ISOTOPE LABELING; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CHEMISTRY; CYTOLOGY; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; METABOLISM; UMBILICAL VEIN;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL PROLIFERATION; ENDOTHELIAL CELLS; EXTRACELLULAR SPACE; FIBRINOLYSIN; GROWTH SUBSTANCES; HUMANS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN CONFORMATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957504489     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-12-28     Document Type: Article

References (42)

1. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. N Ferrara WJ Henzel, Biochemical and biophysical research communications 1989 161 851 858 10.1016/0006-291X(89)92678- 8 2735925 (Pubitemid 19162712)
2. Vascular endothelial growth factor is a secreted angiogenic mitogen. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara, Science (New York, NY) 1989 246 1306 1309 10.1126/science.2479986 (Pubitemid 20066716)
3. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. LF Brown KT Yeo B Berse TK Yeo DR Senger HF Dvorak L van de Water, The Journal of experimental medicine 1992 176 1375 1379 10.1084/jem.176.5.1375 1402682
4. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. N Ravindranath L Little-Ihrig HS Phillips N Ferrara AJ Zeleznik, Endocrinology 1992 131 254 260 10.1210/en.131.1.254 1612003
5. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. P Carmeliet V Ferreira G Breier S Pollefeyt L Kieckens M Gertsenstein M Fahrig A Vandenhoeck K Harpal C Eberhardt,, et al. Nature 1996 380 435 439 10.1038/380435a0 8602241 (Pubitemid 26102719)
6. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. AE Koch LA Harlow GK Haines EP Amento EN Unemori WL Wong RM Pope N Ferrara, J Immunol 1994 152 4149 4156 7511670 (Pubitemid 24111088)
7. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. M Detmar LF Brown KP Claffey KT Yeo O Kocher RW Jackman B Berse HF Dvorak, The Journal of experimental medicine 1994 180 1141 1146 10.1084/jem.180.3.1141 8064230 (Pubitemid 24256627)
8. Vascular endothelial growth factor. The trigger for neovascularization in the eye. N Ferrara, Laboratory investigation; a journal of technical methods and pathology 1995 72 615 618 21622814
9. The biology of vascular endothelial growth factor. N Ferrara T Davis-Smyth, Endocrine reviews 1997 18 4 25 10.1210/er.18.1.4 9034784 (Pubitemid 27076453)
10. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. KA Houck DW Leung AM Rowland J Winer N Ferrara, The Journal of biological chemistry 1992 267 26031 26037 1464614 (Pubitemid 23014012)
11. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. Z Poltorak T Cohen R Sivan Y Kandelis G Spira I Vlodavsky E Keshet G Neufeld, The Journal of biological chemistry 1997 272 7151 7158 10.1074/jbc.272.11.7151 9054410 (Pubitemid 27166421)
12. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. L Jingjing Y Xue N Agarwal RS Roque, Investigative ophthalmology & visual science 1999 40 752 759 21609224 (Pubitemid 29109455)
13. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. C Whittle K Gillespie R Harrison PW Mathieson SJ Harper, Clin Sci (Lond) 1999 97 303 312 10.1042/CS19990016 (Pubitemid 29425324)
14. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. T Lange N Guttmann-Raviv L Baruch M Machluf G Neufeld, The Journal of biological chemistry 2003 278 17164 17169 10.1074/jbc.M212224200 12598527 (Pubitemid 36799595)
15. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. C de Vries JA Escobedo H Ueno K Houck N Ferrara LT Williams, Science (New York, NY) 1992 255 989 991 10.1126/science.1312256
16. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. BI Terman M Dougher-Vermazen ME Carrion D Dimitrov DC Armellino D Gospodarowicz P Bohlen, Biochemical and biophysical research communications 1992 187 1579 1586 10.1016/0006-291X(92)90483-2 1417831
17. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. SY Cheng M Nagane HS Huang WK Cavenee, Proceedings of the National Academy of Sciences of the United States of America 1997 94 12081 12087 10.1073/pnas.94.22.12081 9342366
18. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. P Carmeliet YS Ng D Nuyens G Theilmeier K Brusselmans I Cornelissen E Ehler VV Kakkar I Stalmans V Mattot,, et al. Nature medicine 1999 5 495 502 10.1038/8379 10229225 (Pubitemid 29220207)
19. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. C Ruhrberg H Gerhardt M Golding R Watson S Ioannidou H Fujisawa C Betsholtz DT Shima, Genes & development 2002 16 2684 2698 10.1101/gad.242002 21623591
20. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. S Soker S Takashima HQ Miao G Neufeld M Klagsbrun, Cell 1998 92 735 745 10.1016/S0092-8674(00)81402-6 9529250 (Pubitemid 28155313)
21. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. S Soker HQ Miao M Nomi S Takashima M Klagsbrun, Journal of cellular biochemistry 2002 85 357 368 10.1002/jcb.10140 11948691 (Pubitemid 34274903)
22. Phosphorylation of the growth factors bFGF, NGF and BDNF: a prerequisite for their biological activity. S Klumpp D Kriha G Bechmann A Maaen S Maier S Pallast P Höll J Krieglstein, Neurochem Int 2006 48 131 137 10.1016/j.neuint.2005.08.009 16242215 (Pubitemid 41832448)
23. Detection of ATP-binding to growth factors. S König A Hasche S Pallast J Krieglstein S Klumpp, J Am Soc Mass Spectrom 2008 19 91 95 10.1016/j.jasms.2007.10.010 18055212
24. Fibroblast growth factor 2 requires complex formation with ATP for neuroprotective activity. K Rose S Litterscheid S Klumpp J Krieglstein, Neuroscience 2009 164 1695 1700 10.1016/j.neuroscience.2009.09.055 19782732
25. Binding of ATP to nerve growth factor: characterization and relevance for bioactivity. A Hasche KB Ferenz K Rose S König HU Humpf S Klumpp J Krieglstein, Neurochem Int 2010 56 276 284 10.1016/j.neuint.2009.10.012 19897001
26. ATP-dependent stabilization and protection of fibroblast growth factor 2. K Rose RE Gast A Seeger J Krieglstein S Klumpp, Journal of biotechnology 2010 145 54 59 10.1016/j.jbiotec.2009.10.005 19836424
27. ATP-binding on fibroblast growth factor 2 partially overlaps with the heparin-binding domain. K Rose S Pallast S Klumpp J Krieglstein, Journal of biochemistry 2008 144 343 347 10.1093/jb/mvn072 18511454
28. Purinergic signaling and vascular cell proliferation and death. G Burnstock, Arteriosclerosis, thrombosis, and vascular biology 2002 22 364 373 10.1161/hq0302.105360 11884276 (Pubitemid 34218740)
29. Historical review: ATP as a neurotransmitter. G Burnstock, Trends Pharmacol Sci 2006 27 166 176 10.1016/j.tips.2006.01.005 16487603
30. Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vasorum endothelial cells. EV Gerasimovskaya HN Woodward DA Tucker KR Stenmark, Angiogenesis 2008 11 169 182 10.1007/s10456-007-9087-8 18071915
31. Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis. SM Rumjahn N Yokdang KA Baldwin J Thai IL Buxton, British journal of cancer 2009 100 1465 1470 10.1038/sj.bjc.6604998 19367276
32. A simple modification of Blum's silver stain method allows for 30 minute detection of proteins in polyacrylamide gels. MV Nesterenko M Tilley SJ Upton, J Biochem Biophys Methods 1994 28 239 242 10.1016/0165-022X(94)90020-5 8064118
33. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. BA Keyt LT Berleau HV Nguyen H Chen H Heinsohn R Vandlen N Ferrara, The Journal of biological chemistry 1996 271 7788 7795 10.1074/jbc.271.13.7788 8631822 (Pubitemid 26111064)
34. Investigating the effect of VEGF glycosylation on glycosaminoglycan binding and protein unfolding. B Brandner R Kurkela P Vihko AJ Kungl, Biochemical and biophysical research communications 2006 340 836 839 10.1016/j.bbrc.2005.12.079 16386708 (Pubitemid 43053905)
35. Comparison between light induced and chemically induced oxidation of rhVEGF. ET Duenas R Keck A De Vos AJ Jones JL Cleland, Pharmaceutical research 2001 18 1455 1460 10.1023/A:1012261024249 11697472 (Pubitemid 32977252)
36. Interaction of ATP with fibroblast growth factor 2: biochemical characterization and consequence for growth factor stability. K Rose, BMC Biochemistry 2011 12 14 10.1186/1471-2091-12-14 21447157
37. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. LD Thompson MW Pantoliano BA Springer, Biochemistry 1994 33 3831 3840 10.1021/bi00179a006 8142385 (Pubitemid 24125344)
38. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. RG Keck L Berleau R Harris BA Keyt, Archives of biochemistry and biophysics 1997 344 103 113 10.1006/abbi.1997.0145 9244387 (Pubitemid 27328102)
39. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. SE Sakiyama-Elbert JA Hubbell, J Control Release 2000 69 149 158 10.1016/S0168-3659(00)00296-0 11018553
40. Basic fibroblast growth factor: lysine 134 is essential for its neuroprotective activity. K Rose D Kriha S Pallast V Junker S Klumpp J Krieglstein, Neurochem Int 2007 51 25 31 10.1016/j.neuint.2007.03.011 17524524 (Pubitemid 47002044)
41. The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). CI Seye N Yu FA Gonzalez L Erb GA Weisman, The Journal of biological chemistry 2004 279 35679 35686 10.1074/jbc.M401799200 15175347 (Pubitemid 39100571)
42. Overview of the P2 receptors. JM Boeynaems D Communi NS Gonzalez B Robaye, Semin Thromb Hemost 2005 31 139 149 10.1055/s-2005-869519 15852217 (Pubitemid 40605189)